Test propionate and equipoise cycle

The following additional local adverse reactions are reported infrequently with topical corticosteroids, and they may occur more frequently with high potency corticosteroids, such as Halobetasol Propionate Ointment. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

No metabolites of fluticasone propionate were detected in
an in vitro study of radiolabeled fluticasone propionate incubated in a human
skin homogenate. The total blood clearance of systemically absorbed fluticasone
propionate averages 1,093 mL/min (range, 618 to 1,702 mL/min) after a 1-mg intravenous
dose, with renal clearance accounting for less than % of the total.
Fluticasone propionate is metabolized in the liver by cytochrome P450
3A4-mediated hydrolysis of the 5- fluoromethyl carbothioate grouping. This
transformation occurs in 1 metabolic step to produce the inactive17-ÃŸ-carboxylic
acid metabolite, the only known metabolite detected in man. This metabolite has
approximately 2,000 times less affinity than the parent drug for the
glucocorticoid receptor of human lung cytosol in vitro and negligible
pharmacological activity in animal studies. Other metabolites detected in vitro
using cultured human hepatoma cells have not been detected in man.